| PATENT REGISTER | |||||||||||||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2005/021 2008/018 | |||||||||||||||||||||||||||||||||
| Status | Expired | Patent No. | 0915894 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 97936257.1 | Date of Filing | 25/07/1997 | ||||||||||||||||||||||||||||||
| Date Grant Published | 14/05/2003 | Application Published | 26/01/1998 | ||||||||||||||||||||||||||||||
| Title of Invention | NUCLEOTIDE ANALOGS | ||||||||||||||||||||||||||||||||
| Priority |
|
||||||||||||||||||||||||||||||||
| Inventors |
ARIMILLI, Murty, N. CUNDY, Kenneth, C. DOUGHERTY, Joseph, P. KIM, Choung, U. OLIYAI, Reza STELLA, Valentino, J. |
||||||||||||||||||||||||||||||||
| Current Proprietor |
GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City CA 94404 UNITED STATES OF AMERICA |
||||||||||||||||||||||||||||||||
| Address for service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||||||||||||||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||||||||||||||
| 16/06/2003 | Address for Service recorded as TOMKINS & CO., 5 Dartmouth Road, Dublin 6, IE. | ||||||||||||||||||||||||||||||||
| 12/07/2005 | Request for grant a Supplementary Protection Certificate, citing Patent number 0915894 as the relevent basic patent, in respect of the product Tenofovir disoproxil and salts, hydrates, tautomers and solvates thereof in combination with other theraeutic ingredients, in particular emtricitabine filed on 08/07/2005. Reference number of request is 2005/021. | ||||||||||||||||||||||||||||||||
| 30/05/2008 | Request for grant a Supplementary Protection Certificate, citing Patent number 0915894 as the relevant basic patent, in respect of the product Tenofovir Disoproxil and the salt, in particular the Fumerate, hydrates, tautomers and solvates thereof in combination with Emtricitabine and Efavirenz. filed on 16/05/2008. Reference number of request is 2008/018. | ||||||||||||||||||||||||||||||||
| 11/08/2009 | Supplementary Protection Certificate Number 2005/021, having an expiry date of 20/02/2020 granted on 11/08/2009. | ||||||||||||||||||||||||||||||||
| 11/08/2009 | Supplementary Protection Certificate Number 2008/018, having an expiry date of 24/07/2022 granted on 11/08/2009. | ||||||||||||||||||||||||||||||||
| 18/11/2015 | By virtue of Intangible Licence Agreement dated 01/01/2000 as amended as described in Memorandum of Understanding dated 01/01/2012 Gilead Biopharmaceutics Ireland UC, 25/28 North Way Quay, Dublin 1, Ireland, have been registered as exclusive licensee. Certified copy of Licence on File No. 0915894. | ||||||||||||||||||||||||||||||||
| 16/02/2016 | The expiry date of SPC No. 2005/021 has been amended to bring it into line with the decision from the Court of Justice of the European Union in Case C-471/14. New expiry date is 23/02/2020. | ||||||||||||||||||||||||||||||||
| 01/08/2017 | Patent expired on 24/07/2017. | ||||||||||||||||||||||||||||||||
| 25/10/2017 | A newly executed Licence Agreement dated 30/06/2017 has been filed in connection with the Licence application. This replaces the original filing of the Intangible Licence Agreement on 18/11/2015. | ||||||||||||||||||||||||||||||||
| 22/02/2018 | Application for an extension of the duration of Supplementary Protection Certificate No. 2005/021 filed on 15/02/2018. | ||||||||||||||||||||||||||||||||
| 30/07/2019 | Application for an extension of the duration of Supplementary Protection Certificate No. 2005/021 granted on 30/07/2019. Expiry date of SPC changed from 23/02/2020 to 23/08/2020. | ||||||||||||||||||||||||||||||||
| 03/03/2021 | Supplementary Protection Certificate No. 2005/021 revoked by Order of the High Court dated 11 October 2019. | ||||||||||||||||||||||||||||||||
